CN117320716A - 在医药中应用的4-氯-n-[2-[(4-氯苯基)甲基]-3-氧代-1,2,4-噻二唑-5-基]苯甲酰胺 - Google Patents

在医药中应用的4-氯-n-[2-[(4-氯苯基)甲基]-3-氧代-1,2,4-噻二唑-5-基]苯甲酰胺 Download PDF

Info

Publication number
CN117320716A
CN117320716A CN202280020127.2A CN202280020127A CN117320716A CN 117320716 A CN117320716 A CN 117320716A CN 202280020127 A CN202280020127 A CN 202280020127A CN 117320716 A CN117320716 A CN 117320716A
Authority
CN
China
Prior art keywords
thiadiazol
chlorophenyl
oxo
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280020127.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·埃德伦德
J·韦斯特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagineng Co
Original Assignee
Betagineng Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagineng Co filed Critical Betagineng Co
Publication of CN117320716A publication Critical patent/CN117320716A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280020127.2A 2021-01-12 2022-01-11 在医药中应用的4-氯-n-[2-[(4-氯苯基)甲基]-3-氧代-1,2,4-噻二唑-5-基]苯甲酰胺 Pending CN117320716A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2100352.0 2021-01-12
GBGB2100352.0A GB202100352D0 (en) 2021-01-12 2021-01-12 New methods
PCT/GB2022/050054 WO2022153042A1 (en) 2021-01-12 2022-01-11 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine

Publications (1)

Publication Number Publication Date
CN117320716A true CN117320716A (zh) 2023-12-29

Family

ID=74667674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280020127.2A Pending CN117320716A (zh) 2021-01-12 2022-01-11 在医药中应用的4-氯-n-[2-[(4-氯苯基)甲基]-3-氧代-1,2,4-噻二唑-5-基]苯甲酰胺

Country Status (12)

Country Link
US (1) US20240082222A1 (https=)
EP (1) EP4277625A1 (https=)
JP (1) JP2024505143A (https=)
KR (1) KR20230159375A (https=)
CN (1) CN117320716A (https=)
AU (1) AU2022208237A1 (https=)
BR (1) BR112023013828A2 (https=)
CA (1) CA3208099A1 (https=)
GB (1) GB202100352D0 (https=)
IL (1) IL304392A (https=)
MX (1) MX2023008263A (https=)
WO (1) WO2022153042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
WO2025027205A1 (en) * 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596923A (zh) * 2009-07-08 2012-07-18 波罗的海生物公司 1，2，4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
WO2021074646A1 (en) * 2019-10-18 2021-04-22 Balticgruppen Bio Ab New formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
AU2011281381B2 (en) * 2010-07-21 2015-07-16 Novartis Ag Salt and solvates of a tetrahydroisoquinoline derivative
KR20190009428A (ko) * 2013-10-25 2019-01-28 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
US11691954B2 (en) * 2019-10-18 2023-07-04 Betagenon Ab Formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596923A (zh) * 2009-07-08 2012-07-18 波罗的海生物公司 1，2，4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
WO2021074646A1 (en) * 2019-10-18 2021-04-22 Balticgruppen Bio Ab New formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张骠: "《中药复方药效工程学》", 30 November 2004, 中国医药科技出版社, pages: 256 *

Also Published As

Publication number Publication date
AU2022208237A1 (en) 2023-08-10
CA3208099A1 (en) 2022-07-21
EP4277625A1 (en) 2023-11-22
KR20230159375A (ko) 2023-11-21
WO2022153042A1 (en) 2022-07-21
US20240082222A1 (en) 2024-03-14
AU2022208237A9 (en) 2024-07-25
JP2024505143A (ja) 2024-02-05
IL304392A (en) 2023-09-01
MX2023008263A (es) 2023-09-12
BR112023013828A2 (pt) 2023-10-03
GB202100352D0 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
TW202416937A (zh) 一種藥物組合物及其製備方法和用途
CN117320716A (zh) 在医药中应用的4-氯-n-[2-[(4-氯苯基)甲基]-3-氧代-1,2,4-噻二唑-5-基]苯甲酰胺
JP7771316B2 (ja) 組成物
TW201113050A (en) 3-cyanoquinoline tablet formulations and uses thereof
KR20110102392A (ko) 벤다무스틴의 고체 투약 형태
US20060217355A1 (en) Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer
WO2004054574A1 (ja) 経口固形医薬
AU2014207748B2 (en) Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
RU2258509C2 (ru) Применение олтипраза для профилактики и лечения фиброза и цирроза печени и фармацевтическая композиция, содержащая олтипраз
WO2004032925A1 (en) Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
US20140093563A1 (en) Febuxostat compositions
CN101940569A (zh) 含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用
WO2010110428A1 (ja) 掻痒の予防及び／または治療剤
CN117295492A (zh) 多个他喹莫德粒子及其用途
WO2003022290A1 (en) Medicinal compositions for diabetic neuropathy
US20260060982A1 (en) Use of btk inhibitor and single-dose drug
CN114053282B (zh) 委陵菜酸和山莨菪碱胶囊在制备治疗糖尿病药物中的应用
KR102511672B1 (ko) 의약 조성물, 그 제조방법 및 사용
KR100697097B1 (ko) 당뇨병 예방 또는 치료용 약학 조성물
TW202602438A (zh) 藥物成分、劑型及其製備及使用方法
WO2025218795A1 (zh) 一种药物组合物及其应用
KR20260057455A (ko) Pkc 저해제를 포함하는 약제학적 조성물
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
TW200539859A (en) Methods for increasing neurotransmitter levels using hydroxycitric acid
WO2007055890A2 (en) Co-administration of dehydroepiandrosterone (dhea) congeners and other active agents for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Sweden

Address after: Swedish chicken

Applicant after: Tajinong Co.,Ltd.

Address before: Swedish chicken

Applicant before: Betagineng Co.

Country or region before: Sweden

CB02 Change of applicant information